Although the annual growth rate of the global pharmaceutical industry is generally declining，But the sales of pharmaceutical products have increased unabated。However, economic recession is a practical factor after all，The future change of the pharmaceutical industry is undoubted。 
This year, even if the global economy thaws，Several factors may still restrict the sales growth of drugs，These factors include patent failure、Limited price policy and increased proportion of generic drugs。and a series of major events may also have a long -term impact on the pharmaceutical market，Among them, the reform of the United States through a comprehensive medical care system reform、type A H1N1 flu spread, Stake Sports Bettingetc.My stake betting app。The number of new drug approved by the FDA will still be at a lower level，but，In view of the increase in the incidence of chronic diseases caused by population aging and the increase in per capita medical expenses，The pharmaceutical industry will achieve growth in the future，The level of growth will be reduced。Pharmaceutical Company will start to focus on the focus from North America、Europe and Japan turn to emerging markets。 
Classic is still classic 
Thomson Reuters) Group's pharmaceutical industry prediction tool "Thomson Pharma Partnering Forecast "display，As new drugs enter the market，Some "heavy bombs" drugs want to maintain a leading position in 2010，May face a fight。but，Cardiovascular、Oncology and anti -infection areas should ensure their position in the pharmaceutical market。Dested，Hisine Drug Lipcci and Plateau inhibitors PLAVIX may continue to keep the throne of the top two best -selling drugs。 
As some important products lose patent protection，2010，Prescription drugs worth more than 15.7 billion US dollars will encounter competition of generic drugs。These patented products include Aricept、Flomax、TAXOTERE、EffExor XR、Cozaar and Arimidex。Research and development and treatment products worth looking forward to this year include candidate drugs used to treat central nervous system diseases and diabetes，Both of these areas will achieve sales growth。 
Who is worth looking forward to 
Lipidium reduction medicine Lipteur will undoubtedly continue to become the largest stake sports betting appcategory stake sports betting appdrug，but，The listing of imitation drugs Xinyatin has increased the use of alternative therapeutic products，Lipur's market share gradually shrinks。Market interest still keeps on drugs that can improve high density lipoprotein (HDL) cholesterol。According to the phase III clinical trial data，Compared with a single therapeutic drug，CERTRIAD, which is expected to be pushed to the market, will show greater treatment advantages in multiple blood lipid parameters。 
The potential new products that are expected this year include GlaxoSmith's lipoprotein-related phospholipidase A2 (LP-PLA2) inhibitors Darapladib; ISIS and Genzyme's lipoprotein B-100 antonym Mipomersen，This inhibitor aims to reduce the blood lipids of patients with high risk patients。Two new CETP inhibitors (that is, ANACETRAPIB in Merhadon and DalCetrapib in Roche) is also in the final test stage。 
Anti -antihypertensive drugs In the field of hypertension therapy，Although COZAAR of Merhadon will lose patent protection in April，Vascular tension receptor blockers are expected to be the largest category of drugs。This product patent failure may significantly change the structure of the hypertension treatment drug market，The impact of the sales of such treatment products will continue until the end of next year。Other drug categories in the field of hypertension (such as ACE inhibitors and calcium inhibitors) will continue to occur，and there is no new medicine to push to the market。 
The Tekturna produced stake sports betting appby Novartis is a new type Stake Sports Bettingof direct renal inhibitor，It is expected that the drug will not achieve a rapid sales momentum this year，But it is undoubtedly a big progress in the treatment of hypertension。 
Anti -platelet drugs Bayer and Johnson & Johnson will submit an application for Rivaroxaban to the FDA，Seeking intravenous thromboe embolism that occurs after the treatment of the drug treatment。May 2009，Two companies received a approval letter from FDA。If the final approval is obtained，This medicine will be the first novel oral anticoagulant for the first time to be listed in the past 40 years。but，Thomson Pharma Partnering Forecast of Forecast，Once the medicine is approved to prevent strokes that occur at atrium fibrillation patients，Its maximum growth rate will appear in 2011 and 2012，Because of the alternative product of Warfarin，This product is expected to seize greater market development opportunities。 
Another important anti -platelet drug is Effient，This medicine has considerable competitiveness，It was listed in the United States in August 2009。Once it won the market，It may be possible to compete with Plavix。Clinical trial data indicates，Preventing death、Myocardial infarction and stroke，Effient may be more effective than Plavix，But it may also cause more severe bleeding。Plavix will lose patent protection in 2011。If Lilly gets more research data on the side effects of bleeding，It will undoubtedly provide greater opportunities for Effient。 
Xianlingya is expected Stake Sports Bettingto submit an oral anti-platelet Stake Sports Bettingdrug SCH-530348 this year's listing application。If approved，This medicine will become the first listed product in the novel guboase receptor antagonist。Another new anti -platelet drug、BriLinta developed by Astraikang is the first oral reversal ADP receptor antagonist，It is expected that Astrikan will also submit a listing of the drug to the FDA this year。